We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Siemens Medical Solutions announced that its 550 TxT Treatment Table has received
510(k) clearance from the FDA and is now commercially available in the U.S.
Cygnus announced that it completed the sale of substantially all of its assets
(other than cash and cash equivalents, accounts receivable and its rights in
the arbitration matter with Ortho-McNeil Pharmaceutical) to Animas and Animas
Technologies for $10 million in cash.
Masimo, the inventor of read--through motion and low perfusion pulse oximetry,
announced that a federal court jury in Los Angeles has found that Tyco Healthcare
violated the antitrust laws through anticompetitive business practices specifically
related to the sale of its Nellcor pulse oximetry products.
HemoSense announced the signing of distribution agreements with FDI Medical,
STAT Technologies and Whitmire Medical to market, sell and distribute HemoSense's
INRatio product line to professional healthcare providers in the U.S.
STERIS announced that it has completed the acquisition of FH Surgical SAS, a
privately held manufacturer of surgical tables with approximately 40 employees
and manufacturing facilities in Orleans, France.
MIV Therapeutics (MIVT) announced that its wholly
owned subsidiary, MIVI Technologies -- which is involved in the research and
development of multilayer coating technologies with drug eluting capability
for cardiovascular stents and other implantable devices -- has received a government
grant for the research program titled, "Development of Novel Drug Eluting
Composite Coatings for Cardiovascular Stents."
The first patient was treated at Stanford University Medical Center in a clinical
trial evaluating a drug-coated stent from Cook for peripheral arterial disease
(PAD), a serious medical condition that affects more than 10 million Americans
each year.
The FDA has given Conor Medsystems conditional approval of an investigational
device exemption to begin its COSTAR II pivotal clinical trial to support U.S.
regulatory approval of the company's CoStar stent.